More importantly, the SHH pathway inhibitor Vismodegib has been used as an adjunctive therapy in patients with NBCCS to reduce tumor size and reduce the margins needed for surgical resection29. The gene discussed is SHH; the disease is nevoid basal cell carcinoma syndrome.